Biotechnology | Forum profile

Dow Jones NewsPlus access thru Thursday: http://www.djnewsplus.com/nae/al?rnd=%2FCSZlhgw%2BEZhardEg8KwlQ%3D%3D

One seller in a bad situation that needed to liquidate. Mark

>>It is the indication (and result) that matters<< I appreciate that. My point was that shareholders sold ABGX for a couple of billion three years ago, and in one morning it has added $9bn to AMGN's value. Plenty of 'indications' in the MEDX pipeline. Of course, the 'results' are moot - but then again, I'm not claiming it's worth $9bn. Just that the denosumab news provides a...

You're correct. I don't think they can manage do all of those on this amount. The figure might increase towards the end of the year if there are warrant exercises and/or they manage to strike a deal for the PH-10 business. At the very least, the cash balance gives them some leeway to operate and negotiate.

>...not having any gauge as to what is the normal amount of daily trains traversing the area, the thing that was obvious was the total lack of trains transporting finished goods. 95% of the trains were carrying grain, or in the case of Wyoming…….coal.< Were the trains traveling westbound or eastbound? In the western half of the US, most trains carrying finished are moving eastbound while most trains carrying grain are moving...

Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock SAN DIEGO, July 8, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 12,500,000 shares of its common stock at a public offering price of $4.17 per share. All of the shares are being offered by Arena. The gross proceeds to Arena, before expenses, from the sale of the shares are expected to be...

I don't know of anything "official" with regard to the release of the dosing trial data. I did see an E-mail from UCB IR to someone I know who had E-mailed them and it said they expected to have, and release, data from the dosing trial "Early in the third quarter". That would cause most to think "July", but it doesn't have to be.

The company gives the impression that the liver and psoriasis trials are mostly fully funded. The Phase III melanoma trial would certainly be expensive though. They would almost certainly need some sort of partnership with a blue chip pharma firm and/or licensing of PH-10 to make that work.

"Shares of Aryx Therapeutics were pummeled in premarket trading after the company announced that its trial comparing the experimental blood clotting drug tecarfarin failed to demonstrate superiority over warfarin, a standard treatment. The data was positive for both treatments. Tecarfarin stayed in its target therapeutic range 74 percent of the time while warfarin hit a nearly identical 73.2 percent mark. That's not what...

This is interesting: Letter Nature advance online publication 8 July 2009 | doi:10.1038/nature08221; Received 9 April 2009; Accepted 24 June 2009; Published online 8 July 2009 Rapamycin fed late in life extends lifespan in genetically heterogeneous mice David E. Harrison1,11, Randy Strong2,11, Zelton Dave Sharp3, James F. Nelson4, Clinton M. Astle1, Kevin Flurkey1, Nancy L. Nadon5, J. Erby Wilkinson6, Krystyna Frenkel7, Christy S. Carter8,...